Mans International “Be Your Own Boss” Program is designed to help people from all walks of life around the world who are committed to changing their way of thinking, improving their abilities, and achieving financial freedom and time freedom.
Before You Start
First of all, I’m sorry to tell you that it takes a long time to realize financial freedom and time freedom. If for whatever reason, you have obtained a large amount of wealth, it doesn’t mean that you achieved financial freedom automatically. Because you may not have the ability and psychological capacity to manage large amounts of wealth, the money will be consumed at a rate you can’t imagine.
You might say, can I just ask a financial professional to help me take care of my wealth? The question I asked was do you have the ability to select an outstanding and suitable professional?
If you feel that you ALREADY have independent thinking and various skills, then you do not need to participate in this program! All the best!
Our Values
If you DON’T agree with our values, please do not disturb！
Check Mans International “Be Your Own Boss” program values:
You can either send an email to info@mansinternational.com and we will send you the latest content regularly.
Before You Go
Every year we make plans. Every day we receive tons of information and learn a lot of knowledge, but why most people still can’t make choices that are beneficial to themselves in the long run, achieve their goals, and become a better version of themselves?
这个区别，对我们中国科技创始人来说至关重要。Formation Bio 从来没想过要颠覆药企的整个研发体系，而是精准切入一个“有预算、有紧迫感、有战略压力”的昂贵瓶颈——临床推进环节，这就是我们一直强调的“场景成熟度思维”：不盲目追求技术颠覆，而是找到产业里真实存在的、未被满足的成熟场景，用技术解决具体痛点，才能真正实现价值闭环。
Most AI health startups ask the wrong question: “What can our technology do?”
Formation Bio asked something far more valuable: “Where is value already trapped — and who has the budget to unlock it?”
That single shift explains why Formation Bio has become one of the most closely watched AI-native drug development companies. The company has reportedly raised about $615 million, reached a valuation of around $1.8 billion, and attracted investors including Sam Altman, Sequoia Capital, and Andreessen Horowitz.
But the real lesson is not that Formation Bio “uses AI.” The real lesson is that Formation Bio chose a mature commercial scenario before scaling the technology. That is what most AI health startups miss.
The Real Bottleneck Was Never Drug Discovery
For years, the dominant AI drug development story has been about discovery:
Find new targets
Generate new molecules
Predict biological behaviour faster than humans
But Formation Bio’s founder and CEO, Ben Liu, saw a different bottleneck.
“Pharma does not lack promising molecules. It lacks a faster, cheaper, more reliable way to move drugs through clinical development.”
Clinical trials are slow, expensive, operationally complex, and filled with execution risk. TIME recently reported that Formation Bio is focused on accelerating administrative and analytical tasks related to trials. Formation Bio:
Buys or in-licenses “stalled” assets — drugs already discovered but shelved by big pharma due to budget cuts, strategic shifts, or portfolio pruning
Uses proprietary AI to “stress-test” and accelerate trials — optimizing patient recruitment, site selection, and protocol design
De-risks and out-licenses — creating value through speed, not novelty
That distinction matters. Formation Bio is not trying to replace pharma’s entire R&D system. It is attacking a painful, expensive bottleneck in a system already facing budget constraints, urgency, and strategic pressure.
That is Scenario Maturity Thinking.
What Is Scenario Maturity?
Scenario Maturity is the difference between a technology that looks impressive and a business that can actually convert.
A mature scenario has three pillars:
The Scenario Maturity Compass
1. Business Maturity
Who actually buys?
Who owns the budget?
Why would they act now?
2. Workflow Maturity
Can the solution fit into real-world operations?
Or does it require customers to change behaviour, rebuild infrastructure, and take on new risk?
3. Data Maturity
Does usage create better data?
Does better data improve the system?
Does that improvement compound into a defensible advantage?
When these three pillars align, revenue has a pathway. When one breaks, even excellent technology can stall.
This is why I often tell founders: technology does not generate revenue on its own. Scenario maturity creates the conditions for revenue.
Clear Buyer Convergence: Who Actually Pays?
Many AI health startups fail because they build for users rather than buyers.
They build for clinicians, patients, researchers, or health platforms — but cannot answer the most important commercial question: Who signs the purchase order?
Formation Bio identified their buyer early: Pharma business development & clinical operations teams at companies like Sanofi and Eli Lilly.
Have multi-billion dollar R&D budgets
Face intense pressure to improve time-to-market
Already understand the value of de-risked late-stage assets
This buyer convergence creates:
Shorter sales cycles (no market education needed)
Higher contract values (ROI is quantifiable: months saved = millions earned)
Strategic partnership opportunities (not just vendor relationships)
Workflow Maturity: AI Embedded Into the Real Job
One of the biggest mistakes AI startups make is selling AI as a product.
Formation Bio avoids this trap. In partnership with OpenAI and Sanofi, Formation Bio launched Muse, an AI tool designed to analyze scientific literature and generate tailored patient recruitment materials, cutting recruitment timelines from months to minutes.
Muse is embedded into Formation Bio’s trial acceleration workflow. Customers don’t buy “AI correlation.” They buy:
Lower trial costs → higher margin on out-licensed assets
Reduced execution risk → more predictable ROI
This is the key lesson for founders: AI becomes valuable when it disappears into the workflow and improves the business outcome.
If your customer has to stop, learn, reconfigure, and take on extra operational risk to use your product, your scenario maturity is low.
Data Maturity: The Closed Loop Most Startups Never Build
Most AI health startups face a “cold start” problem:
Data is fragmented across EHRs, wearables, and trials
Feedback loops are weak or non-existent
Model improvements don’t compound into business value
Formation Bio engineered a closed data loop:
Clinical trial execution → Real-world trial data → AI model iteration → Faster, cheaper next trial → Higher asset valuation
This creates:
Compounding advantage: Each trial makes the platform smarter
Defensible moat: Proprietary trial execution data can’t be scraped or replicated
Investor confidence: Clear path to margin expansion as the platform scales
This isn’t just a biotech story. It’s a scenario selection story — and it applies to every complex market.
The Kintsugi Contrast
This is why the contrast between Kintsugi and Formation Bio is so important.
Kintsugi had impressive technology: AI-based voice biomarkers for detecting depression. It had a compelling mission, clinical signal, and strong investor interest.
But the commercial scenario was much harder.
Who pays?
Hospitals?
Employers?
Health plans?
Digital health platforms?
Clinics?
Each buyer had different incentives, budgets, workflows, and risk concerns.
That created a scenario maturity gap.
Formation Bio, by contrast, chose a clearer buyer, a known pain point, a measurable ROI, and a workflow where AI could improve execution without requiring the whole market to change first.
That is the difference between promising technology and investable momentum.
Why This Matters for Every Tech Founder
Formation Bio’s lesson is universal: Success isn’t about better tech — it’s about smarter scenario selection.
Before you scale, ask:
Budget vs. Buzz: Is there an existing procurement line for your solution — or just interest?
Fit vs. Friction: Does your product plug into existing workflows, or require behaviour change?
Leverage vs. Labour: Does every customer make your system stronger — or add custom work?
Causation vs. Correlation: Can your buyer measure ROI in cost savings, revenue gains, or risk reduction?
If your technology is strong but revenue is slow, the problem may not be the product.
It may be your scenario maturity.
At Mans International, this is exactly what we help founders diagnose: where your product is getting stuck, why the market is not converting, and what must change before investors, customers, or strategic partners are ready to move.
Our expertise lies in Scenario Maturity Thinking — helping founders assess whether their technology is entering a market where the buyer, budget, urgency, data, and value-capture logic are mature enough to support real commercialization.
Because in today’s market, the winners are not always the companies with the most impressive technology.
They are the companies that know exactly where value is trapped, who has the incentive to unlock it, and how to convert that insight into revenue, partnership, and scale.
Everyone thinks LVMH just invested $5 million in WTHN, a New York-based modern wellness platform that operationalizes Traditional Chinese Medicine (TCM) as a premium, omnichannel ritual system. They’re reading the headline, not the strategy. LVMH didn’t fund a treatment modality — they funded the re-architecture of status.
We are witnessing the birth of Luxury 2.0: a shift where longevity, bio-optimization, and ritualized self-care are replacing the leather goods of the past. In this new era, the ultimate flex isn’t what you carry — it’s how long you’ll live to enjoy it.
Wellness is the Luxury 2.0
The recent move by L Catterton (LVMH’s investment arm) into WTHN isn’t a “wellness play.” It’s a masterclass in Strategic Translation.
The global wellness economy reached a record $6.8 trillion in 2024 and is projected to grow at a robust annual rate of 7.6%, surpassing $9.8 trillion by 2029. This represents a significant acceleration, with the wellness sector now accounting for 6.1% of total global GDP. LVMH is not experimenting. It is claiming strategic ground early.
Traditional TCM speaks in qi, meridians, and balance. WTHN speaks in stress relief, recovery, and hormonal optimization. This is not a simplification. This is strategic narrative repositioning. They didn’t export culture. They reframed value into a category the market understands.
2. Precision Targeting
WTHN doesn’t serve “everyone.” It targets:
high-pressure urban professionals
women 20–40
Gen Z & Millennials investing in self-optimization
These consumers feel acute pain points (burnout, sleep disruption), have purchasing power, and are willing to pay for measurable transformation.
3. Full-Stack Commercial Loop
Most traditional players break at distribution. WTHN closes the loop:
Offline: premium acupuncture & cupping experience → trust building
Online: beautifully designed home-use products → repeat consumption
This creates brand stickiness, recurring revenue, and defensible unit economics.
4. Experience as Luxury
WTHN is positioned not as a clinic, but as an experience. Prime locations (e.g., Manhattan), minimalist, high-end design, curated sensory environments, and premium pricing transform each session into a deliberate act of self-investment. This is exactly what luxury demands.
Case Study: Why WTHN Won Where Cha Ling Stalled
This is not LVMH’s first attempt.
Its earlier brand, Cha Ling, followed a different path. The comparison is revealing:
Cha Ling (2016) vs. WTHN (2024)
LVMH’s TCM Strategic Evolution Cha Ling 2016 vs. WTHN 2024
• Cha Ling: Heritage alone cannot justify premium pricing without experiential depth
• WTHN: Scalable TCM requires service architecture + UX design + cultural translation
Final Thought: The Cultural Translator’s Edge
LVMH’s investment is a strategic vote for a specific type of founder: The Cultural Translator.
The next generation of winners won’t be pure technologists or pure traditionalists. They will be the ones who can anchor themselves in deep tradition while operating with the surgical precision of modern business systems.
In the global market, tradition is not your constraint — your narrative is.
For Founders
If your product isn’t converting, it’s rarely the technology.
Last week, I sat down with several health tech founders to stress-test their business models. The conversation kept circling back to a hard truth: in health tech, brilliant technology doesn’t guarantee survival.
In February 2026, Kintsugi — a pioneer in AI-powered voice biomarkers for depression detection — announced it was winding down commercial operations. This was not a failure of science. The company had developed models trained on tens of thousands of voice samples, demonstrated genuine clinical promise, and generated real enterprise interest. So what went wrong?
1. The “New Category” Trap
Kintsugi was selling into a nascent market: AI-based mental health diagnostics. That immediately triggers three enterprise questions that are genuinely hard to answer quickly:
Is it clinically accurate?
Is it biased across accents, languages, or demographics?
Who bears liability when it misses or misclassifies?
Answering these requires years of market education. Education is time-consuming, capital-intensive, and rarely aligns with venture pacing. Clinically, early depression detection matters. Commercially, it rarely triggers a fast procurement cycle.
2. Correlation ≠ Causation
I emphasize this to founders constantly: buyers don’t pay for correlation. They pay for causation.
Even if your model detects depression with high sensitivity, a health system will ask a precise follow-up: “How does this move our specific metrics?” Early detection benefits patients, but you must prove it lowers acute care spend or improves value-based reimbursement performance. Mental health tools often create profound long-term clinical value. Enterprise buyers, however, operate on short-term budget logic. That gap is the seller’s problem to close, not the buyer’s problem to overlook.
3. Buyer Ambiguity Kills Momentum
This is where I apply the Scenario Maturity Assessment Framework (SMAF) — a diagnostic I used to help founders identify exactly where they are in the buyer-readiness lifecycle before committing capital to a sales motion.
The Scenario Maturity Assessment Framework asks a foundational question most founders skip: not “who could benefit from this?” but “which buyer, in which scenario, is mature enough to act right now?” Maturity here means they have the budget authority, the internal problem recognition, and the procurement trigger already in motion.
Kintsugi’s addressable market included hospitals, telehealth platforms, clinics, and employers. On an SMAF assessment, this maps to a fragmented scenario landscape. When you’re navigating multiple buyers with divergent incentives, compliance requirements, and approval timelines, the result is predictable: no one buys quickly.
The discipline SMAF enforces is uncomfortable but non-negotiable: identify the one buyer scenario where maturity is highest, build your entire first commercial motion around that wedge, and treat every other segment as a future phase — not a current pipeline.
The Runway vs. Regulatory Mismatch
Then came the structural wall. Kintsugi pursued FDA De Novo clearance for a novel AI diagnostic category. That pathway demands years of evidence generation, expensive consultants, iterative submissions, and regulatory uncertainty. The company reportedly exhausted its runway waiting for final clearance.
Venture timelines expect product-market fit in 18 to 24 months; healthcare regulatory pathways operate on a 5- to 7-year horizon. That gap demands you design your funding strategy, commercial roadmap, and regulatory sequence as a single, integrated plan from day one.
What Founders Should Take From This
Kintsugi’s shutdown is not a repudiation of voice biomarker science. The underlying research remains valid. This is a structural lesson about what it takes to survive long enough to commercialize a genuinely novel clinical technology in a regulated environment.
Before your next raise, pressure-test these three questions and be honest about the answers:
Who exactly will sign the PO? (Not who could benefit, but who holds the budget, authority, and incentive to buy now?)
What causation outcome triggers the purchase? (Cost avoidance? Risk mitigation? Reimbursement lift?)
Does your runway cover the full clearance-to-commercialization timeline? (If not, what non-clinical or bridge revenue extends it?)
As AI and deep tech redefine the possible, I have witnessed countless brilliant founders fail. They don’t fail because their technology is flawed; they fail because they chase “cool tech” without validating Scenario Maturity.
In high-stakes innovation, hype doesn’t pay the bills. To navigate this, I leverage a rigorous Scenario Maturity Assessment Framework, a methodology pioneered by enterprise AI leaders like Zheng Yan at Huawei Cloud. It serves as a “Scenario Compass,” separating true signal from noise.
Today, I apply this framework to one of the most explosive—and misunderstood—frontiers in the global market: Brain-Computer Interface (BCI).
The Scenario Compass: Three Critical Questions for Growth-Stage Founders
For growth-stage founders, the challenge shifts from validation to scale. This framework determines whether you become a unicorn or a cautionary tale:
Business Maturity: Is there a scalable procurement pathway? Who owns the P&L?
Data Maturity: Does your data pipeline create a defensible moat? Does the workflow generate continuous improvement loops?
Technology Maturity: Is your technology deployment-ready for commercial scale, or are you relying on roadmap promises?
Scenario Maturity Assessment Framework
Deconstructing BCI: Four Scenarios, Four Realities
Brain-Computer Interface (BCI) is one of the most hyped AI frontiers today. Yet, when you apply scenario maturity, the picture becomes much clearer.
1. Medical Rehabilitation
Business Maturity (High): Payers are clear (patients, insurance, rehab hospitals).
Data Maturity (High): Clinical data exists. Each patient interaction generates natural, labelled data streams.
Technology Maturity (Medium): Invasive BCI is human-validated.
This is the most sustainable long-term play for serious capital.
The moat is expensive to dig, but impenetrable when complete.
Global Framework, Local Execution: The China Case Study
While the Scenario Maturity Framework is universal, its application requires localized intelligence. In 2026, China stands as the definitive testing ground.
Global BCI financing reached $1.3 billion between 2025 and 2026. Remarkably, Chinese BCI financing in Q1 2026 alone surpassed the full-year total of 2025.
The strategic signal is unequivocal: In 2026, China elevated BCI to a National Strategic Priority within the Government Work Report, categorizing it under “New Quality Productive Forces” (新质生产力).
Why Global Founders Stall in China
Even with great tech, foreign founders often hit a wall in China because they ignore the nuances of the Scenario Compass:
The “Medical Bridge” Requirement: Many try to jump straight to consumer apps. In China, medical certification (NMPA) is the “trust badge” that unlocks consumer confidence and institutional scaling.
The Data Sovereignty Wall: Neural data is the ultimate “Personal Information.” Under China’s Personal Information Protection Law (PIPL), a localized data storage and compliance strategy is mandatory from Day 1.
Local Competition: Companies like Xiangyu Medical are already moving through the maturity matrix. Speed to localization is your only defence.
Your Strategic Next Steps
Is your technology aligned with market reality, or are you building in a vacuum?
Are you burning cash on low-maturity consumer scenarios while high-maturity medical paths are open?
Do you have a roadmap to leverage the world’s fastest-growing BCI ecosystem without losing your IP?
Contact us to assess your product’s commercial readiness. Together, let’s transform your technology into a market-leading reality.
At Mans International, we help founders and investors bridge the gap between global innovation and localized market reality.
[Contact Us] to schedule a confidential strategic session.
Together, let’s transform your technology into a market-leading reality.
AI is no longer measured by the model, but by the Token.
Two landmark moves have quietly re-indexed the global AI landscape:
NVIDIA officially reframed the data centre as a “Token Production Factory.”
Alibaba launched the Alibaba Token Hub (ATH), making token throughput a core corporate pillar.
Together, they signal something much bigger: We are entering a Token Economy.
1. The Token: The Marginal Cost of Thought
A token is often described as the smallest unit an AI processes. For a strategist, that definition is noise.
A token is the atomic unit of cost in digital reasoning.
Every time an agentic system reads, decides, or acts, it is “burning” tokens—and therefore consuming your margin. This reframes AI from a technical capability to an economic system.
Every token carries a Strategic Trilemma:
Compute: The silicon cycles required to generate it.
Energy: The literal wattage consumed by the AI Factory.
Latency: The time tax imposed on the end-user experience.
The frontier has moved: From Model Scale → To Intelligence Density.
The new objective is uncompromising: Maximize high-order reasoning per token.
2. The Global Infrastructure: Two Visions of the Factory
The race for the Token Economy has bifurcated into two strategic archetypes: The Utility and The Sovereign.
NVIDIA: The Vertical Utility
NVIDIA has outgrown the “chipmaker” label. It is now the Foundry of Intelligence. By securing a 500-megawatt “AI Factories” partnership with Saudi Arabia’s HUMAIN, NVIDIA is moving upstream to control the raw materials of reasoning: Compute, Energy, and Scale.
The Goal is to become the foundational utility layer. NVIDIA doesn’t just enable models; it powers the continuous, global production of digital thought.
Alibaba Token Hub (ATH): The Full-Stack Sovereign
If NVIDIA is building the grid, Alibaba is building the Closed-Loop Economy. Led directly by CEO Eddie Wu, ATH represents a decisive move toward Full-Stack Sovereignty. Alibaba has integrated the entire Token lifecycle into a single operating model:
Create: Foundational intelligence (Tongyi Lab)
Deliver: Cloud-scale distribution (AliCloud/Bailian)
Alibaba is building infrastructure for a market where JPMorgan forecasts Token Consumption in China could grow at 330% CAGR through 2030. Alibaba is positioning itself to own the entire value chain of a digital superpower.
3. The New KPI: Token Efficiency
In the Token economy, the new lead indicator of enterprise health is Intelligence per Token.
More tokens do not equal better results; they equal higher costs and slower cycles. Competitive advantage now belongs to the High-Efficiency Architect —extracting maximum reasoning from minimum inference.
The New KPI: Token Efficiency
For the C-Suite: P&L statements will transition from “Headcount” to “Inference Budgets.” Profitability will no longer be determined by how many people you employ, but by your Token Margin—the value created vs. the tokens consumed.
For Talent: The fundamental career question has changed. It is no longer: “What can you do?” It is: “How effectively can you deploy AI?”
4. The Strategic Mandate
The Token Economy represents the formal industrialization of intelligence. In this new stack, value creation is distributed across four distinct layers:
Production: The “Factory” layer (Compute, Silicon, Energy).
Distribution: The “Grid” layer (Cloud platforms and high-availability APIs).
Application: The “Agentic” layer (AI-native products and autonomous systems).
Optimization: The “Refinery” layer (Compression, orchestration, and inference efficiency).
The Four Layers of Value Creation in the Token Economy
The winners will not necessarily dominate all four layers, but they will control a critical bottleneck within one of them.
The question for founders and investors is simple: What is your stake in the Token Economy? Because in the next decade, competitive advantage will not come from simply “having AI”, but from how efficiently you produce and deploy it.
About Mans International: A global strategic firm specializing in the intersection of AI, China Strategy, and Digital Transformation. We advise the architects of the new economy.
The next decade of AI value requires more than data — it requires cultural fluency, local intelligence, and structured access.
For years, the global AI conversation focused almost entirely on model capability: larger datasets, larger clusters, and stronger reasoning systems.
But a new reality is emerging.
The global AI landscape is now evolving along two distinct but complementary tracks:
Track 1 — Frontier Intelligence
Led primarily by companies such as OpenAI and Google DeepMind, this track focuses on advancing reasoning, multimodal systems, and general intelligence.
Track 2 — Physical Deployment
China’s ecosystem is rapidly becoming the world’s largest laboratory for industrializing embodied AI, turning intelligent systems into machines that operate at scale.
For founders, success in this new landscape no longer comes from choosing one track.
The most competitive companies of the next decade will treat them as two layers of the same global AI stack.
Frontier intelligence may emerge from research labs.
But the cost curve of intelligent machines — and the data generated by their real-world operation — will increasingly be shaped by deployment ecosystems.
Case Study: The Industrialization of Intelligence
A clear example of this deployment-driven ecosystem is AgiBot (智元机器人), a Shanghai-based robotics company led by former Huawei engineer Peng Zhihui.
Instead of focusing on demonstration prototypes, AgiBot has concentrated on industrial deployment at scale.
Image source: www.agibot.com
1. Market Leadership
According to the latest industry analysis by Omdia, global humanoid robot shipments reached approximately 13,000 units in 2025.
AgiBot emerged as the largest supplier:
5,168 units shipped in 2025
39% global market share
In practical terms: Nearly two out of every five humanoid robots shipped globally last year came from AgiBot.
This is not laboratory experimentation.
It is an industrial-scale deployment.
2. The Price Revolution
AgiBot’s Lingxi X2 Youth Edition humanoid robot is currently priced at approximately 98,000 yuan (~$13,500 USD).
By pushing the cost of humanoid robotics below the $15,000 threshold, AgiBot has transformed embodied AI from a research novelty into a commercially deployable asset.
In other words, the “body” of AI is becoming affordable infrastructure.
Image source: www.agibot.com
3. Business Model Innovation: Robot-as-a-Service
AgiBot has also introduced a new platform called Qingtian Rental (擎天租), effectively creating a Robot-as-a-Service (RaaS) model.
Early adoption metrics are striking:
200,000+ registered users within three weeks
200+ daily rental orders
The strategic implication is significant. By lowering access barriers through leasing, AgiBot is aggregating massive volumes of real-world operational data — data that is extremely difficult to replicate in laboratory environments.
Over time, this data becomes a powerful moat for improving robot intelligence and reliability.
Why the Ecosystems Are Diverging
China’s rapid progress in AI deployment is not accidental. It emerges from three structural conditions that shape how innovation occurs within its ecosystem.
1. Scarcity-Driven Engineering
Silicon Valley’s AI boom has been fueled by abundance:
massive venture capital
large GPU clusters
deep research institutions
China’s ecosystem evolved under tighter constraints.
Export controls and intense domestic competition forced engineers to optimize aggressively.
Instead of brute-force scaling, many Chinese teams focus on:
hardware–software integration
compute-efficient training
system-level optimization
In a world where inference costs are rising, this culture of extreme efficiency may become a decisive advantage.
2. Infrastructure as a Shared Platform
In many Western ecosystems, AI infrastructure is primarily a private asset.
In China’s major technology hubs — such as Shanghai and Shenzhen — AI computing centers often function as shared productivity platforms.
Startups can plug into regional:
datasets
testing environments
computing resources
This dramatically lowers the cost of experimentation and accelerates deployment across industries.
3. Long-Horizon Capital
China has also mobilized large pools of patient capital to support strategic technologies.
Government-backed funds frequently operate on 10–15-year investment horizons.
This allows deep-tech founders to pursue industrialization strategies — such as humanoid robotics — that are difficult to sustain in shorter venture cycles.
The Mans International Strategic Perspective
The emerging Dual-Track AI world does not require founders to choose a side.
It requires architectural fluency across both systems.
The most successful companies of the next decade will combine:
Frontier intelligence from advanced research ecosystems
Industrial deployment through manufacturing and infrastructure networks
Operational data generated by real-world intelligent systems
Because in the next phase of AI competition:
Your model can be replicated in months. Your supply chain cannot. Your policy access cannot. Your real-world deployment data cannot.
Those are the moats that matter.
At Mans International, we work with founders, investors, and technology leaders navigating the intersection of Chinese technology, culture, and global markets. With a deep understanding of the AI deployment ecosystem, policy implications, and industry support, we help leaders bridge the gap between “frontier intelligence” and “physical deployment.” This is no longer an option—it is the ultimate strategic advantage.
A Final Question for Founders:
“Your model can be replicated in months. Your supply chain cannot. Your policy access cannot. Your data moat cannot. Which of these are you actually building?”
In the dual-track reality, the advantage goes to those who can see the whole map.
Book your Strategic Advisory at info@mansinternational.net
